(FM) Oncología
Departamento académico
Medical University of Vienna
Viena, AustriaPublications en collaboration avec des chercheurs de Medical University of Vienna (14)
2024
2023
-
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles
Cell Reports Medicine, Vol. 4, Núm. 12
2022
-
Current practice in proton therapy delivery in adult cancer patients across Europe
Radiotherapy and Oncology, Vol. 167, pp. 7-13
-
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268
2021
-
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma
Virchows Archiv, Vol. 478, Núm. 2, pp. 153-190
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
Radiotherapy and Oncology, Vol. 154, pp. 327-353
-
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
International Journal of Gynecological Cancer, Vol. 31, Núm. 1, pp. 12-39
-
Lenvatinib in Patients With Advanced Grade 1/2 Pancreatic and Gastrointestinal Neuroendocrine Tumors: Results of the Phase II TALENT Trial (GETNE1509)
Journal of Clinical Oncology, Vol. 39, Núm. 20, pp. 2304-2312
2019
-
Olaparib plus bevacizumab as first-line maintenance in ovarian cancer
New England Journal of Medicine, Vol. 381, Núm. 25, pp. 2416-2428
2018
-
Safety and dose modification for patients receiving niraparib
Annals of Oncology, Vol. 29, Núm. 8, pp. 1784-1792
2016
-
Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer
Annals of Oncology, Vol. 27, Núm. 11, pp. 2046-2052
-
Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): A randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICOENGOT- GCIG intergroup study (HECTOR)
Annals of Oncology, Vol. 27, Núm. 12, pp. 2236-2241
2013
-
Safety and efficacy of everolimus with exemestane vs. Exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2
Clinical Breast Cancer, Vol. 13, Núm. 6, pp. 421-432.e8
2006
-
Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia
Journal of the National Cancer Institute, Vol. 98, Núm. 4, pp. 273-284